Healthcare [ 5/11 ] | Biotechnology [ 72/148 ]
CA | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 3, 23 | 0.11 Increased by +650.00% | 0.13 Decreased by -15.38% |
| May 4, 23 | -0.14 Decreased by -125.93% | -0.12 Decreased by -16.67% |
| Feb 21, 23 | -0.10 Decreased by -152.63% | -0.01 Decreased by -1.80 K% |
| Nov 8, 22 | 0.08 Increased by +200.00% | 0.05 Increased by +60.00% |
| Aug 9, 22 | -0.02 Decreased by -100.00% | -0.02 Decreased by -28.45% |
| May 10, 22 | 0.54 Increased by +45.95% | 0.38 Increased by +42.11% |
| Feb 24, 22 | 0.19 Decreased by -56.82% | 0.19 |
| Nov 9, 21 | -0.08 | -0.05 Decreased by -60.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 10.06 M Decreased by -78.10% | -30.53 M Decreased by -349.93% | Decreased by -303.58% Decreased by -1.95 K% |
| Mar 31, 23 | 12.19 M Decreased by -96.15% | -40.11 M Decreased by -123.79% | Decreased by -328.99% Decreased by -717.84% |
| Dec 31, 22 | 21.55 M Decreased by -84.54% | -29.89 M Decreased by -149.86% | Decreased by -138.75% Decreased by -422.48% |
| Sep 30, 22 | 101.38 M Increased by +1.74 K% | 26.62 M Increased by +224.53% | Increased by +26.26% Increased by +106.77% |
| Jun 30, 22 | 45.92 M Increased by +66.11% | -6.79 M Decreased by -192.08% | Decreased by -14.78% Decreased by -75.84% |
| Mar 31, 22 | 316.58 M Increased by +56.15% | 168.57 M Increased by +43.81% | Increased by +53.25% Decreased by -7.90% |
| Dec 31, 21 | 139.33 M Decreased by -32.98% | 59.95 M Decreased by -48.76% | Increased by +43.03% Decreased by -23.54% |
| Sep 30, 21 | 5.51 M Decreased by -41.17% | -21.38 M Decreased by -693.91% | Decreased by -388.16% Decreased by -1.25 K% |
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.